CTOs on the Move

Respicardia

www.respicardia.com

 
Founded in 2006 and headquartered near Minneapolis, Minnesota, Respicardia® is dedicated to improving the lives of heart failure patients by developing implantable therapies designed to improve Respiratory Rhythm Management and cardiovascular health. The remedē® System is an innovative implantable stimulation device designed to restore natural breathing during sleep for patients with Central Sleep Apnea.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.respicardia.com
  • 12400 Whitewater Dr Suite 150
    Minnetonka, MN USA 55343
  • Phone: 952.540.4470

Executives

Name Title Contact Details

Funding

Respicardia raised $58.5M on 12/19/2017

Similar Companies

www.pontotoctech.edu

Pontotoc Technology Center (PTC) has a diverse economy with a large health community including Mercy Hospital, Chickasaw Nation Health System and Rolling Hills Psychiatric Hospital. Pontotoc also has a large mining sector with Holcim, Unimin, and Fairmount Minerals, a large manufacturing sector with Flex-N-Gate and Solo Cup and a large service industry with Pre Paid Legal Services dba Legal Shield and Interactive Response Technologies. These diverse sectors are served in a rural setting.

PTW New York Corporation

PTW New York Corporation is a Hicksville, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Medrecon

Medrecon is a Garwood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Scribe Healthcare Technologies

Scribe Healthcare Technologies is a Lake Forest, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Sight Sciences

Founded in 2011, Sight Sciences develops and commercializes intelligently designed and engineered products that target the underlying causes of the world`s most prevalent eye diseases. The company`s surgical glaucoma product portfolio features the OMNI Surgical System, a dually indicated MIGS device that facilitates the performance of both ab interno trabeculotomy and transluminal viscoelastic delivery. Using proprietary multi-modal functionality, OMNI allows surgeons to target all three sources of resistance in the conventional outflow pathway (trabecular meshwork, Schlemm`s canal and collector channels) with a single device and single corneal incision. The company`s non-surgical dry eye product portfolio consists of the TearCare for ophthalmologists and optometrists. TearCare is a software-controlled, wearable, therapeutic eyelid technology designed to melt and clear obstructions of the meibomian glands within the eyelids. Leveraging the full functionality of the blinking eye, proprietary SmartLid™ technology is designed to conform to all eyelid anatomies and achieve therapeutic meibum melting temperatures at the tarsal conjunctiva thereby clearing meibomian gland obstructions while sparing the cornea. Improved meibum production results in a higher quality lipid layer and higher quality tears.